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Introduction  
Thyrotoxicosis along with its usual signs and symptoms like palpitation, weight loss, tremors, 
sweating, heat intolerance, diarrhea, exophthalmos, tachycardia, and warm extremities, can also 
present with gynaecomastia and as many as 80% of the patients may have histological evidence 
of gynaecomastia1-4. Although association of thyrotoxicosis with gynaecomastia is well 
documented, its presentation as the initial or the predominant compliant in a subject with 
undiagnosed hyperthyroidism is extremely rare5. Gynaecomastia in thyrotoxicosis may 
predominate over other commonly recongnized symptoms. A patient who presented with tender 
unilateral gynaecomastia secondary to thyrotoxicosis is described. 
Case Report  
A 52 year old man was referred for evaluation of gynaecomastia. He had history of a tender lump 
on the right breast and difficulty in walking for the past two months. He also complained of 
weight loss and disturbed sleep for the last three months. He was married and had three children 
and denied any sexual problems. On physical examination his weight was 54kg, pulse rate 
96/minute and blood pressure 130/70 mmHg. Fine tremors of both hands were present and there 
was no proptosis and thyroid was not enlarged. Heart rate was 96/minute with no murmur or 
gallop. 
Examination of chest showed that the right breast had a 2 x 2 cm tender mobile lump under the 
areloa. Left breast was normal. He had difficulty in getting up from squatting position without 
support. Rest of the physical examination was unremarkable. 
Chest X-ray, complete blood count, fasting blood suguar and urine analysis at the time of 
presentation were within normal limits. He was advised to get his thyroid functions done which 
revealed free thyroxine (fT4) 3.9 ng/dl (0.8-1.9), thyroid stimulating hormone (TSH) <0.1uU/ML 
(0.40-4.0), serum sodium chloride and bicarbonate were within normal limits whereas serum 
potassium (K) was 3.6 mmol/L (3.8-5.2). He was prescribed Carbimazole 30 mg daily and 
propranolol 10 mg TID. On follow-up visit six weeks later, his physical examination revealed 
that his weight was 57 Kg, blood pressure 120/80 mmHg, pulse 72/minute and there were no 
tremors. He could easily get up from squatting position without support. The lump in the right 
breast had completely receded. His fT4 was 0.9 ng/dl and serum K was 3.9 mmol/L. TSH was 
still suppressed to <0.1 p.IU/ml. 
Discussion  
Gynaecomastia is common in teen age boys, obese and elderly men and in patients suffering 
from chronic liver disease. Drug induced gynaecomastia is also frequent whereas other causes of 
gynaecomastia are relatively uncommon6. 
Association of gynaecomastia with hyperthyrodisim is uncommon but has been well documented 
Gynaecomastia in patients with hyperthyrodisim is rarely present as a primary complaint. When 
present, it may pose a diagnostic challenge to the clinician7. 
Information on the effect of abnormal thyroid function on male reproduction is more scanty than 
that for the females8. It has been noticed that patients with thyrotoxicosis have elevated 
androstenedione production rate9 that leads to subsequent increased production of estrogens in 
extraglandular sites. Therefore the mechanism of elevated estrogen is probably similar to that in 
liver disease i.e., increased availability of substrate for extraglandular aromatisation10. 
Progesterone has also been found higher in hyperthyroid patients before treatment. Progesterone 
also enhances estrogen’s stimulation of mammary gland”. Androstenediole and androstenedione 
are active metabolites of dehydroepiandrosterone (DHEA) and DHEA sulphate respectively and 
have estrogenic activity. Concentration of Adioles, DHEAS and pregnanolone sulphate in blood 
are increased in hyperthyroidism. Thyroid hormones may stimulate the synthesis of these 
steroids contributing to gynaecomastia in hyperthyroidism12. A case of gynaecomastia, 
galactorrhea and hypokalaemic paralysis with hyperthyroidism is also documented13. Our patient 
also showed slightly lower values of potassium which returned to normal without potassium 
supplement. 
When there are no obvious causes to explain gynaecomastia, hyperthyroidism should be 
considered as a posibility. 
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